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Abstract: 16 
Antibody technologies are being increasingly applied in the field of toxinology. Fuelled by the many advances in 17 
immunology, synthetic biology, and antibody research, different approaches and antibody formats are being 18 
investigated for the ability to neutralize animal toxins. These different molecular formats each have their own 19 
therapeutic characteristics. In this review, we provide an overview of the advances made in the development of 20 
toxin-targeting antibodies, and discuss the benefits and drawbacks of different antibody formats in relation to their 21 
ability to neutralize toxins, pharmacokinetic features, propensity to cause adverse reactions, formulation, and 22 
expression for research and development (R&D) purposes and large-scale manufacturing. A research trend seems to 23 
be emerging towards the use of human antibody formats as well as camelid heavy-domain antibody fragments due to 24 
their compatibility with the human immune system, beneficial therapeutic properties, and the ability to manufacture 25 
these molecules cost-effectively. 26 
Keywords: Antivenom; venom; recombinant antivenom; antibodies; snakebite; scorpion sting; spider bite; animal 27 
envenoming; pharmacokinetics; pharmacodynamics; immunogenicity; venom neutralization; antibody expression; 28 
antivenom design; adverse reaction; neglected tropical diseases; biotechnology 29 
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1. Introduction 31 
The world fauna presents a vast variety of venomous animals including snakes, scorpions, spiders, bees, wasps, 32 
caterpillars, sea anemones, jellyfishes, lizards, fishes, and cone snails as examples. Many of these animals can cause 33 
severe envenomings by their sting or bite, inflicting pain, tissue damage, and systemic pathologies, and may in some 34 
cases cause fatalities. The true number of these accidents is unknown, as even the World Health Organization (WHO) 35 
does not report epidemiological data for envenomings by all classes of venomous animals. However, it has been 36 
estimated that snakes alone cause 1.8 to 2.7 million envenomings each year, resulting in 81,000 to 138,000 deaths 37 
(Gutiérrez et al., 2017a), while scorpion stings result in 1.2 million envenomings per year, leading to around 3,000 38 
deaths (Chippaux and Goyffon, 2008). In particular, snakebite envenoming is classified by the WHO as a Neglected 39 
Tropical Disease (NTD), a group of diseases that prevail in tropical and subtropical parts of the world and mainly affect 40 
populations living in poverty with very limited access to healthcare. 41 
The specific medical treatment for envenomings caused by animals is the use of antivenoms. Heterologous 42 
antivenom serotherapy is a century-old treatment described simultaneously by Césaire Auguste Phisalix, Gabriel 43 
Bertrand, and Albert Calmette in France in 1894 (Calmette, 1894; Phisalix and Bertrand, 1894). Later (1901), in Brazil, 44 
Vital Brazil Mineiro da Campanha demonstrated that antivenom specificity is essential for treating envenomings from 45 
particular species (Hawgood, 1992). Since that time, the use of antivenoms has saved countless lives. Nowadays, 46 
different heterologous antivenoms are manufactured in many countries with the aim of neutralizing venoms from 47 
diverse venomous animal species (Laustsen et al., 2016a). Supplies of these life-saving medicines are, however, still 48 
critically scarce in many regions (Brown and Landon, 2010), and efforts are being carried out to improve their 49 
availability and accessibility (Gutiérrez, 2012). 50 
Although heterologous antivenoms are, to this date, the only effective treatment for snakebite envenomings, these 51 
therapeutic agents present some documented undesirable problems (Fig. 1): (i) Antivenoms can cause anaphylactic 52 
reactions, which can be either IgE-mediated or, more commonly, non-IgE-mediated (due to complement activation); 53 
both types are known as early adverse reactions (up to 24 h) (de Silva et al., 2011; Geoffrey K. Isbister et al., 2008; León 54 
et al., 2013). (ii) Antivenoms are composed of whole immunoglobulins (IgGs) or antigen-binding fragments (F(ab')2s or 55 
Fabs) raised against whole venom(s) via immunization of a host animal (Laustsen et al., 2016a, 2016c; 56 
Rodríguez-Rodríguez et al., 2016). However, the majority of these antibodies are not directed towards medically 57 
relevant venom toxins (Laustsen et al., 2015), but are instead directed against antigens that the immunized animal has 58 
encountered during its life (environmental antigens, microorganisms, and parasites). As a consequence, most 59 
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antivenoms carry a large portion of immunoglobulins that are not directed against venom components (about 70%) 60 
(Laustsen et al., 2016a; Segura et al., 2013). (iii) The large amount of antivenom antibodies combined with the elicited 61 
human anti-horse antibodies (IgGs and IgMs) may result in the generation of immune complexes (ICs) that have a long 62 
elimination half-life. This can trigger IC deposition in target tissues (such as blood vessels, glomeruli, and joints), 63 
mediating inflammation and promoting serum sickness – a late adverse reaction associated with type III hypersensitivity 64 
(1-2 weeks after antivenom therapy) (Cunningham et al., 1987; Descotes and Choquet-Kastylevsky, 2001). 65 
Taken together with the high cost of antivenom production, which is dependent on both animal immune systems 66 
and procurement of venoms, a need for innovation within envenoming therapies exists. Several approaches, including 67 
the use of immunization with DNA, synthetic epitope strings, or recombinant toxins, have been pursued (Alvarenga et 68 
al., 2002; Araujo et al., 2003; Harrison, 2004; Laustsen et al., 2016a, 2016c). However, despite a promising potential for 69 
eliminating the need for keeping venomous animals in captivity and "milking" them to obtain their venoms, these novel 70 
immunization techniques all retain the drawbacks of creating heterologous antivenoms with compromised compatibility 71 
with the human immune system. A more recent avenue that has been taken is the development of recombinant 72 
antibodies and antibody fragments of camelid and/or human origin (Harrison et al., 2011; Laustsen et al., 2016a, 2016c; 73 
Pucca et al., 2012; M.B. Pucca et al., 2011; Richard et al., 2013). These molecules have very low immunogenicity and 74 
are easy to engineer using standard approaches that are well-investigated in other fields. This allows for the design of 75 
more optimized envenoming therapies with better safety profiles and potentially higher efficacy, as such recombinant 76 
antibodies would be completely compatible with the human immune system. Furthermore, only therapeutically active 77 
antibodies targeting medically relevant toxins would be included in a novel recombinant antivenom (Laustsen et al., 78 
2015). Additionally, in the future it is projected that the production of recombinant antivenoms based on mixtures of 79 
such antibodies may be cost-effective compared to traditional antivenom manufacturing methods (Laustsen et al., 2017, 80 
2016b). However, although several antibody formats have been investigated for use in recombinant antivenoms (Fig. 2), 81 
a clear indication of which format represents the optimal molecular scaffold to be used does not exist. In this review, we 82 
therefore aim at presenting all available data on different antibody formats that have been investigated for neutralization 83 
of animal toxins, and discuss their pros and cons in relation to toxin targeting in clinical scenarios. 84 
 85 
2. Pharmacodynamics: Ability to neutralize venom toxins 86 
Pharmacodynamics (PD) plays a key role in the successful outcome of antivenom immunotherapy. Within the 87 
field of antivenom, PD refers to the ability of therapeutic molecules to neutralize in vivo specific venom toxins present 88 
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in a given venom, which is one of the key determinants of antivenom efficacy. Independent of their antibody format, 89 
antivenoms derive their PD efficacy from high affinity interactions between each antibody-toxin pair, although antibody 90 
stability was also considered important for neutralization capacity (Juárez-González et al., 2005) In the simple situation 91 
involving only a single antibody and a single toxin, affinity is often reported using the dissociation constant, Kd. 92 
However, several factors complicate such measurements when comparing classical polyclonal antivenoms: (i) several 93 
different antivenom antibodies (with different specificities) may recognize the same or various epitopes in a single 94 
toxin; (ii) each individual antivenom antibody may recognize similar (homologous) toxins with different affinities; (iii) 95 
the concentration of each antibody that recognizes a given toxin is unknown. For these reasons, it is only feasible to 96 
measure the avidity (a measure of the strength between a venom and multiple antibodies), also interpreted as functional 97 
affinity (Casewell et al., 2010; Vauquelin and Charlton, 2013). To our knowledge, no studies have systematically 98 
investigated the effect on avidity after enzymatic treatment of polyclonal IgGs to Fabs (or F(ab')2s). However, one may 99 
expect a higher avidity of an IgG or F(ab')2-based antivenom than a Fab-based antivenom due to the bivalent nature of 100 
the IgG and F(ab')2 formats. The two independent binding sites on these antibody formats provides a larger probability 101 
that toxin will become rebound to the antibody if the toxin is released due to molecular proximity effects. Additionally, 102 
cross-linking to other toxin-antibody complexes can take place, making it less likely that a toxin may escape during 103 
transient dissociation of the complex (Rudnick and Adams, 2009). This cross-linking effect may potentially lead to high 104 
therapeutic relevance of weaker interactions. Nevertheless, at least one Fab-based antivenom has proven not to be less 105 
effective in the clinical setting than an IgG-based antivenom (Dart and McNally, 2001). 106 
Monoclonal IgGs and single-chain variable fragments (scFvs) are the primary recombinant antibody formats that 107 
have been investigated for neutralization of animal toxins. In vivo lethality studies assessing the neutralization capacity 108 
of several monoclonal IgGs have shown positive results for snake toxins (Charpentier et al., 1990; Frauches et al., 2013; 109 
Stiles et al., 1994), spider toxins (Alvarenga et al., 2003; Boulain et al., 1982), and scorpion toxins (Bahraoui et al., 110 
1988; Clot-Faybesse et al., 1999; Zamudio et al., 1992) as summarized in Tables 1-3, respectively. Studies testing 111 
neutralization through biochemical assays have additionally found promising results against both snake toxins (Boulain 112 
et al., 1982; Charpentier et al., 1990; Trémeau et al., 1986) and scorpion toxins (Alvarenga et al., 2005) for the IgG 113 
format. In addition, many studies focusing on snake venom toxins have discovered IgGs with neutralizing abilities 114 
against multiple specific toxins responsible for myonecrosis (Frauches et al., 2013; Li et al., 1993; Lomonte et al., 1992; 115 
Lomonte and Kahan, 1988), haemorrhage (Fernandes et al., 2010; Frauches et al., 2013; Iddon et al., 1988; Morine et al., 116 
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2008; Perez et al., 1984; Schneider et al., 2014; Tanjoni et al., 2003b), and proteolytic effects (Morine et al., 2008; 117 
Schneider et al., 2014), as shown in Table 1. 118 
Another of the most commonly investigated antibody formats is the Fab format. Two different studies produced 119 
Fabs against snake toxins. In one study, a Fab targeting cardiotoxin from Naja nigricollis venom was developed 120 
(Guillon et al., 1986), and in another study a Fab was develop against β1-bungarotoxin from Bungarus multicinctus 121 
venom (Yang and Chan, 1999). Both Fabs were shown to neutralize in vitro and in vivo effects of the toxins, 122 
respectively. Four studies have developed monoclonal Fabs against spider and scorpion toxins. Of these, three exhibited 123 
neutralizing effects in vivo against spider toxins (Bugli et al., 2008) and scorpion toxins (Licea et al., 1996; Selisko et 124 
al., 2004), whereas the last study did not obtain neutralizing Fab antibodies (Aubrey et al., 2004). As previously 125 
mentioned, the scFv antibody format has also been widely studied. scFvs showing neutralization of lethality in vivo 126 
have been reported for both snake toxins (Cardoso et al., 2000; Castro et al., 2014; Kulkeaw et al., 2009; Lee et al., 2015; 127 
Meng et al., 1995; Oliveira et al., 2009; Roncolato et al., 2013) and scorpion toxins (Amaro et al., 2011; Devaux et al., 128 
2001a; Hmila et al., 2012; Mousli et al., 1999; Riaño-Umbarila et al., 2016, 2013, 2011, 2005; Rodríguez-Rodríguez et al., 129 
2016). To obtain more biochemical details regarding scorpion toxin neutralizing capacity, electrophysiological studies 130 
involving the two-electrode voltage clamp technique using Xenopus laevis frog oocytes showed that activation of 131 
sodium channels by Tityus serrulatus venom toxins Ts1, Ts2, and Ts5 could be neutralized by human scFvs (Pucca et 132 
al., 2014). Also, scFvs capable of neutralizing myonecrosis have been reported for snake venom toxins (Oliveira et al., 133 
2009; Roncolato et al., 2013; Tamarozzi et al., 2006). Other scFvs have been discovered, which can neutralize melittin 134 
and phospholipase A2 (PLA2) from Africanized bees in vitro and prolong survival in vivo (see Table 4). However, scFvs 135 
that lack neutralizing abilities have also been reported (Juárez-González et al., 2005). In addition to assessing their 136 
neutralization potential, a few studies of scFv antibodies developed against snake venom toxins also include a structural 137 
and sequencing analysis to determine the regions involved in toxin binding (Kulkeaw et al., 2009; Lafaye et al., 1997; 138 
Meng et al., 1995). 139 
Several studies have involved two other small antibody formats, variable fragments of heavy chain antibodies 140 
(VHHs) and dimers of scFvs (diabodies), used against snake and scorpion toxins. Of these, one VHH has shown 141 
neutralization of lethality against snake toxins (Richard et al., 2013), whereas both VHHs (Abderrazek et al., 2009; 142 
Hmila et al., 2012, 2008, 2008) and diabodies (di Tommaso et al., 2012; Rodríguez-Rodríguez et al., 2012) have shown 143 
neutralization of lethality against scorpion toxins. For IgGs (Bahraoui et al., 1988; Boulain et al., 1982; Charpentier et al., 144 
1990; Fernandes et al., 2010; Iddon et al., 1988; Jia et al., 2000; Schneider et al., 2014; Trémeau et al., 1986), Fabs 145 
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(Aubrey et al., 2004), scFvs (Juárez-González et al., 2005; Lafaye et al., 1997; Lee et al., 2015; Meng et al., 1995; 146 
Riaño-Umbarila et al., 2016, 2013, 2011, 2005; Rodríguez-Rodríguez et al., 2016), and VHHs (Abderrazek et al., 2009; 147 
Hmila et al., 2008; Richard et al., 2013; Stewart et al., 2007) some studies have determined the Kd between the antibodies 148 
and their respective toxins. The Kds range from 10 µM as the highest reported for an scFv against crotoxin from the 149 
venom of the South-American rattlesnake (Lafaye et al., 1997) to the lowest Kd of 28 pM for an IgG developed against 150 
BmK AS-1 from the Chinese scorpion Buthus martensii Karsch (Jia et al., 2000). The reported Kds seem to corroborate 151 
the notion that high affinity frequently correlate with better neutralization ability, where antibodies with neutralizing 152 
abilities have Kds in the lower nanomolar range, as shown in Table 1 and Table 3.  153 
All reported monoclonal antibody formats that have been developed against snake, scorpion, spider, and bee 154 
venom toxins seem to neutralize toxins equally well (see Tables 1-4). No conclusion can thus be drawn on which format 155 
binds and neutralizes animal toxins best. However, one major challenge when comparing different antibody formats is 156 
that studies have employed very different approaches for assessing toxin neutralization. For better comparison of 157 
neutralization potentials of different antibodies, it would be beneficial if a common approach could be employed, such 158 
as that recommended by the WHO for assessing the preclinical efficacy of antivenoms. Following this approach, in vivo 159 
neutralization is assessed by pre-incubation of toxin and antibody prior to injection into rodents, as this has been shown 160 
to yield the best reproducibility of results and allow for better comparability between antivenoms (Gutiérrez et al., 161 
2017b). This protocol does, however, not mimic a real life envenoming and subsequent treatment scenario, and 162 
antibodies showing neutralization potential when pre-incubated with the toxin prior to injection may not show efficacy 163 
if administered after venom injection (Charpentier et al., 1990). It would therefore be more relevant to evaluate 164 
antivenom neutralizing capacity in experiments involving independent administration of venoms and antibodies, i.e. 165 
‘rescue experiments’. Overall and unsurprisingly, no final conclusion can be drawn based purely on pharmacodynamics 166 
regarding which antibody format represents the most optimal format for toxin neutralization. To allow for better 167 
comparison between different antibody formats it would be beneficial to test a single monoclonal antibody and its 168 
derived formats against the same toxin target, given that no prior studies have been performed within the field of 169 
toxinology. 170 
 171 
2.1. Modes of neutralization 172 
Understanding the modes of neutralization of antibodies may guide the design of novel antivenom components. 173 
Nonetheless, only limited efforts have been invested in this area, and it is therefore not possible to determine any 174 
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general trend in how different antibody formats neutralize various animal toxins. However, studies of single antibodies 175 
targeting mainly snake venom toxins have proposed five different mechanisms to explain the mode of neutralization. 176 
Firstly, direct inhibition where antibodies interfere with the site of interaction between the toxin and its target by 177 
competitive inhibition (Fig. 3A). This mechanism has been demonstrated for an anti-long chain neurotoxin monoclonal 178 
antibody (Charpentier et al., 1990) and has been suggested as a general mode of neutralization of small neurotoxins by 179 
polyvalent antivenoms (Engmark et al., 2017a, 2016). For enzymatic toxins, direct inhibition may be equivalent to 180 
blocking the catalytic site (Fig. 3B). Similar to direct inhibition, binding of a relative large antibody (fragment) to a 181 
region near the site of interaction may result in a steric hindrance effect (Fig. 3C). However, to the best of our 182 
knowledge no record of such situation is available, although it is structurally feasible. A third mechanism is allosteric 183 
inhibition (Fig. 4), where binding of the antibody induces a conformational change making a toxic site inaccessible or 184 
locking the toxin in a much less toxic, or even inactive, conformation. As an example, a polyvalent Crotalinae 185 
antivenom has been reported to recognize linear peptides mimicking a known allosteric site from snake venom serine 186 
proteases (Engmark et al., 2017b). Fourthly, antibodies can prevent the dissociation of toxin complexes responsible for 187 
forming the active toxins (Lafaye et al., 1997) (Fig.5). Fifthly, even if an antibody does not block the active site of the 188 
toxin nor an allosteric site, the formation of toxin-antibody complexes may preclude the toxin from interacting with its 189 
target, and may facilitate its elimination by the mononuclear phagocytic system (Gutiérrez and León, 2009).  190 
On the more general level of venom toxicity, neutralization of single toxins by antibodies may reduce the clinical 191 
manifestations dramatically. This may be explained by high individual toxicity and/or high concentration of a single 192 
toxin in a venom (Laustsen et al., 2015), and when this toxin is neutralized, only weakly toxic or non-toxic components 193 
remain. However, abrogation of venom toxicity by a single antibody can also be caused by an interruption of synergistic 194 
effects between toxins, if a key toxin (or key component) is neutralized (Fig. 6). Toxin synergism is a well-known 195 
feature of certain snake venoms (Laustsen, 2016). Each venom toxin may exhibit low toxicity on its own, but when the 196 
individual toxins are combined in a whole venom, they amplify the effect of each other resulting in actions such as 197 
destabilization of phosphorylative oxidation and increased tissue necrosis (Gasanov et al., 2014). Consequently, 198 
understanding the toxicity and interplay between individual toxins, as well as possible mechanisms of neutralization, is 199 
key to rational design of future recombinant antivenoms. Therefore, despite the great biochemical complexity of snake 200 
venoms (Calvete, 2017) and other animal venoms, it is likely that, in some cases, the neutralization of a few key toxins 201 
by antibodies may result in a drastic reduction in overall venom-induced toxicity. 202 
  203 
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Table 1. Reported antibodies and antibody fragments against snake venom toxins 204 
Antibody 
format 
Snake  Toxin Origin Kd (nM) Therapeutic effect Ref. 
Myotoxic 
effects 
Haemotoxic 
effects 
Biochemical 
assay 
Lethality 
Not 
neutralizing 
 
IgG1 Echis carinatus  Whole venom Murine  
 In vivo 
 
  
(Iddon et al., 
1988) 
IgG2a, 
IgG2b 
Naja naja oxiana  Neurotoxin I Murine  
  
 
In vivo  
(Stiles et al., 
1994) 
IgM, IgG1, 
IgG2b 
Bothrops asper BaP1 Murine In the nM 
range 
 In vivo 
 
  
(Fernandes et al., 
2010) 
IgG Naja naja 
siamensis  
α-cobratoxin Murine Estimated at 
2.1-3.7  
  
In vitro 
  
(Charpentier et 
al., 1990) 
IgG1, IgM Bothrops atrox  Atroxlysin-I Murine 8.52 - 15.10  In vivo    (Schneider et al., 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Toxicon 2018, FOR PEER REVIEW 2 of 31 
 
2014) 
IgG Bothrops atrox  Murine   
In vivo In vivo 
 
In vivo  
(Frauches et al., 
2013) 
IgG2a Naja nigricollis,  
Laticauda 
semifasciata,  
Laticauda 
colubrina, 
Naja mossambica 
and 
Naja naja atra  
Toxin α, 
Erabutoxin b and 
c, 
Toxin d, 
Toxin I and III 
and Cobrotoxin 
Murine 2- 1.500  
  
In vitro 
  
(Trémeau et al., 
1986) 
IgG1 Bothrops jararaca Jarahagin Murine  
 In vivo 
 
   
(Tanjoni et al., 
2003b) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Toxicon 2018, FOR PEER REVIEW 3 of 31 
 
IgG1 
 
Agkistrodon 
contortrix 
lacticinctus  
Myotoxin Murine  
In vivo  
 
  
(Li et al., 1993) 
IgG Crotalus atrox  Murine  
 In vivo 
 
  
(Perez et al., 
1984) 
IgG2a Naja nigricollis  Toxin α Murine 0.35  
  
In vitro 
In vivo  
(Boulain et al., 
1982) 
IgG1, IgM Bothrops asper  Myotoxin Murine   
In vivo  
 
  
(Lomonte and 
Kahan, 1988) 
IgG1 Probothrops 
flavoviridis 
HR1a Human  
 In vivo 
 
  
(Morine et al., 
2008) 
scFv Crotalus durissus 
terrificus  
Crotoxin Murine 0.2-7.4  
  
 
In vivo  
(Meng et al., 
1995) 
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scFv Crotalus durissus 
terrificus 
Subunit B 
Crotoxin 
(II-PLA2) 
Human 10,000  
  
 
 
 
 
(Lafaye et al., 
1997) 
scFv Naja kaouthia Long alfa 
neurotoxin  
Human  
  
 In vivo 
 
 
(Kulkeaw et al., 
2009) 
scFv Bothrops asper  BaP1 Not 
specified 
 
 In vivo 
 
In vivo  
(Castro et al., 
2014) 
scFv Vipera ammodytes 
meridionalis 
Vipoxin (PLA2) Human  
 In vitro 
 
  
(Stoyanova et al., 
2012) 
scFv Bothrops 
jararacussu 
All the PLA2 
isoforms of the 
venom 
Human  
In vivo  
 
In vivo  
(Roncolato et al., 
2013) 
scFv Bothrops BthTXI and Human  In vivo      (Tamarozzi et al., 
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jararacussu BthTX-II PLA2 2006) 
scFv Crotalus durissus 
terrificus 
Subunit B 
Crotoxin 
(II-PLA2) 
Human  
In vivo  
 
In vivo   
(Oliveira et al., 
2009) 
scFv Crotalus durissus 
terrificus  
Crotoxin Human  
  
 
In vivo  
(Cardoso et al., 
2000) 
VHH  Naja kaouthia α-cobratoxin Camelid 2.0-3.0  
  
 
  
(Stewart et al., 
2007) 
VHH/IgG Naja kaouthia α-cobratoxin Camelid 0.4-25  
  
 
In vivo  
(Richard et al., 
2013) 
VH/VHH Naja kaouthia PLA2  Camelid  
  
In vitro 
  
(Chavanayarn et 
al., 2012) 
 205 
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Table 2. Reported monoclonal antibodies and antibody fragments against spider venom toxins 206 
Antibody format Spider Toxin Origin Kd (nM) Therapeutic effect Reference 
Lethality Not neutralizing 
IgG Loxosceles intermedia unknown Murine    (Alvarenga et al., 
2003) 
Fab Latrodectus tredecimguttatus α-latrotoxin Murine  In vivo   
(Bugli et al., 2008) 
IgG Loxosceles intermedia SmaseD Murine  In vivo    
(Dias-Lopes et al., 
2014) 
 207 
Table 3. Reported monoclonal antibodies and antibody fragments against scorpion venom toxins 208 
Antibody Scorpion Toxin Origin Kd (nM) Therapeutic effect Reference 
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format Biochemical 
assay 
Lethality Not neutralizing 
IgG Androctonus australis AahII Murine 0.8  In vivo  (Bahraoui et al., 
1988) 
IgG1, IgG2a, 
IgG2b 
Androctonus australis hector AahI Murine   In vivo  (Clot-Faybesse et al., 
1999) 
IgG Buthus martensi  BmK 
AS-1 
Murine 0.0278- 
0.152 
   (Jia et al., 2000) 
IgG2a, IgG1 Centruroides noxius Cn2 Murine   In vivo  (Fernando Zamudio et 
al., 1992) 
IgG1 Tityus serrulatus  Murine  In vitro   (Alvarenga et al., 
2005) 
Fab Androctonus australis AahI Murine 0.082    x (Aubrey et al., 2004) 
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Fab Centruroides noxius  Cn2 Murine   In vivo  (Selisko et al., 2004) 
Fab Centruroides noxius Cn2 Murine   In vivo  (Licea et al., 1996) 
scFv Androctonus australis AahII Murine   In vivo  (Mousli et al., 1999) 
scFv Androctonus australis AahI Murine   In vivo  (Devaux et al., 2001b) 
scFv Centruroides noxius Cn2 Human 1.01   In vivo  (Riaño-Umbarila et 
al., 2005) 
scFv Centruroides noxius Cn2 Murine 0.075   x (Juárez-González et 
al., 2005) 
scFv Centruroides noxius and Centruroides suffusus 
suffusus  
Cn2 and 
Css2 
Human 0.05-16.60  In vivo  (Riaño-Umbarila et 
al., 2011) 
scFv Centruroides 
suffuses, Centruroides limpidus, Centruroides 
noxius and Centruroides tecomanus 
Css2, 
Css4,  
Cll1, Cll2,  
Human 1-290  In vivo  (Rodríguez-Rodríguez 
et al., 2016) 
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Cn2,  
Ct1a 
scFv Centruroides noxius and Centruroides limpidus 
limpidus 
Cll1 and 
Cn2 
Human 8.1-25.1   In vivo  (Riaño-Umbarila et 
al., 2013) 
scFv  Centruroides noxius. Cn2 Human 
 
5.4-93.7  In vivo  (Riaño-Umbarila et 
al., 2016) 
scFv Tityus serrulatus  Ts1 Human   In vivo  (Amaro et al., 2011) 
scFv Tityus serrulatus Whole 
venom 
Human     (Pucca et al., 2012) 
scFv Tityus serrulatus Ts1 and 
Ts2 
Human  In vitro   (Pucca et al., 2014) 
VHH 
 
Androctonus australis  AahI Camelid  1.21-55.8  In vivo  (Hmila et al., 2008) 
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VHH Androctonus australis  AahII Camelid 0.12-76.00  In vivo  (Abderrazek et al., 
2009) 
VHH Androctonus australis  AahI and 
AahII 
Camelid   In vivo  (Hmila et al., 2010) 
VHH Androctonus australis AahI and 
AahII  
Camelid   In vivo  (Hmila et al., 2012) 
 
Diabody 
mixture  
Androctonus 
Australis 
AahI and 
AahII 
Murine    In vivo  (di Tommaso et al., 
2012) 
 
Diabody  Centruroides noxius Cn2 Human 0.0369-0.095   In vivo  (Rodríguez-Rodríguez 
et al., 2012) 
Table 4. Reported monoclonal antibodies and antibody fragments against bee venom toxins 209 
Antibody Bee Toxin Origin Kd Therapeutic effect Reference 
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format (nM) Myotoxic 
effects 
Hemotoxic 
effects 
Biochemical 
assays 
Lethality 
Not 
neutralizing 
scFv  Apis 
mellifera 
Mellitin and 
PLA2 
Murine   In vivo  In vivo  (Santos et al., 2013) 
scFv Apis 
mellifera 
Mellitin and 
PLA2 
Human  In vivo     (Funayama et al., 2012; 
Pessenda et al., 2016) 
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3. Pharmacokinetics: Distribution and elimination of antibodies and antibody fragments 210 
The efficacy of treatment for a therapeutic antibody is strongly influenced by the speed and concentration at which 211 
it reaches the site of action, as well as its residence time in the body and consequent elimination. Upon injection, the 212 
pharmacological effect of the antibody will vary according to its absorption, distribution, metabolism, and excretion 213 
(ADME), pharmacokinetic (PK) processes that depend largely on the structural and biophysical properties of the 214 
molecule (Deng et al., 2012; Liu, 2017; Mould and Green, 2010). The combination of these processes provides an 215 
antibody with a PK profile, generally described by parameters such as volume of distribution (Vd), bioavailability (F), 216 
clearance (CL), maximum concentration in plasma (Cmax), and elimination half-life (t1/2), among others, that are 217 
calculated after measuring the concentration in plasma of the antibody over a period of time after its administration (Fan 218 
and de Lannoy, 2014).  219 
Generally, for antibodies and their fragments, there is a strong relationship between the molecular mass of the 220 
molecule and its distribution and elimination characteristics. The PK profiles of recombinant monoclonal IgG 221 
antibodies used for therapeutic purposes (isotypes IgG1, IgG2, and IgG4) are characterized by limited tissue distribution 222 
and long elimination half-lives (Fig. 7A-B), displaying either linear or non-linear (dose-dependent) profiles (Kamath, 223 
2016; Keizer et al., 2010; Tabrizi et al., 2006). Distribution of IgGs, which involves extravasation to the interstitial space 224 
and elimination from tissue, occurs mainly by convection, as diffusion across endothelial cells is very slow due to the 225 
large size and hydrophilicity of the molecule (Lobo et al., 2004). Their large size also impedes IgGs from being 226 
enzymatically metabolized by cytochrome P450 (Mould and Green, 2010), and cleared by the kidneys (glomerular 227 
filtration cut-off ~50 kDa) (Wang et al., 2008). Instead, the main route for their elimination is via intracellular 228 
catabolism in the lysosomes, upon fluid-phase endocytosis (pinocytosis) or receptor-mediated endocytosis, including 229 
binding to Fcγ receptors (FcγR) expressed by phagocytic cells (Keizer et al., 2010; Tabrizi et al., 2006; Wang et al., 230 
2008). However, a major fraction of the internalized IgGs is rescued from rapid degradation through binding to the 231 
neonatal Fc receptor (FcRn) of cells in the mononuclear phagocyte system (Fig. 7C), which transports the IgGs back to 232 
the cell surface and facilitates their release into the extracellular fluid (Brambell et al., 1964; Junghans, 1997); this is a 233 
saturable, pH-dependent, recycling mechanism that confers a long half-life (21-28 days) to human IgGs (Keizer et al., 234 
2010; Raghavan et al., 1995; Tabrizi et al., 2006; Wang et al., 2008). Of note, the affinity of IgGs for FcRn is species 235 
dependent (Ober et al., 2001). Human IgGs have a higher affinity for human FcRn than chimeric IgGs and murine IgGs, 236 
which explains the shorter elimination half-lives of the latter in humans (∼8–10 days and ∼1–3 days, respectively) 237 
(Deng et al., 2012; Tabrizi et al., 2006). 238 
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In contrast to whole IgGs, the smaller sizes of antibody fragments, such as Fabs, scFvs (monomers and dimers),  239 
VHHs, and minibodies, account for a larger volume of distribution and faster rate of tissue penetration (Harmsen and De 240 
Haard, 2007; Keizer et al., 2010; Wu et al., 1999, 1996). Due to the lack of an Fc region on these antibody fragments, 241 
they are unable to bind to the FcRn. Also associated with their small size, the main route for their clearance is via 242 
glomerular filtration by the kidneys (Lobo et al., 2004; Tabrizi et al., 2006). Owing to these features, these antibody 243 
fragments possess considerably shorter half-lives (0.5-30 h) (Tabrizi et al., 2006). F(ab´)2 fragments, also devoid of Fc 244 
region, possess a shorter half-life than IgGs, since recycling by the FcRn rescue mechanism is not possible (Tabrizi et 245 
al., 2006). However, their distribution profile resembles that of IgGs, and similarly, elimination occurs mainly by 246 
non-renal mechanisms, as their size exceeds the cut-off for renal filtration (Seifert and Boyer, 2001; Tabrizi et al., 247 
2006). 248 
In addition to the structural and biophysical properties of the antibody molecule, PK of IgGs and their fragments 249 
can be influenced by specific patient conditions, such as age, gender, health status (renal and hepatic function), or 250 
concomitant administration of other drugs (Deng et al., 2012; Tabrizi et al., 2006). The interaction between the antibody 251 
and the antigen may also affect on PK (Bauer et al., 1999; Meijer et al., 2002), as well as immune responses against the 252 
antibody itself that may shorten its half-life (de Vries et al., 2007; Xu et al., 2008). Recently, several strategies to 253 
prolong the half-lives of antibodies and their fragments have been explored, such as mutations in the Fc region to 254 
increase affinity towards FcRn (Dall’Acqua et al., 2006; Finch et al., 2011; Monnet et al., 2014), N-glycosylation (Stork 255 
et al., 2008), polysialylation (Chen et al., 2012; Constantinou et al., 2008), PEGylation (Chapman et al., 1999), 256 
modification of the isoelectric point (Boswell et al., 2010; Kobayashi et al., 1999), and fusion or binding to proteins 257 
having an extended half-life (e.g. albumin, immunoglobulin) (Andersen et al., 2011; Evans et al., 2010; Hutt et al., 2012; 258 
Müller et al., 2007; Sleep et al., 2013; Smith et al., 2001; Unverdorben et al., 2012). 259 
In agreement with the PK parameters displayed by whole recombinant IgGs and their fragments used as 260 
therapeutics, kinetic studies of plasma-derived antivenoms have shown the same strong relationship between the 261 
molecular mass of the molecules and their PK profiles (Gutiérrez et al., 2003). Antivenoms based on IgGs have low 262 
volumes of distribution, long elimination half-lives, and a high number of cycles through the interstitial spaces (Ho et 263 
al., 1990; Ismail et al., 1998; Ismail and Abd-Elsalam, 1996). Conversely, antivenoms based on Fab fragments, much 264 
smaller than IgGs, have larger volumes of distribution, diffuse faster into extravascular compartments, and have shorter 265 
elimination half-lives (Ariaratnam et al., 2001, 1999; Brvar et al., 2017; Meyer et al., 1997; Rivière et al., 1997; H. 266 
Vázquez et al., 2010; Vázquez et al., 2005). A negative consequence of the short elimination half-life of Fab fragments 267 
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is the higher incidence of recurrent peaks in plasma venom levels, and therefore envenomation symptoms, compared to 268 
IgG and F(ab´)2 antivenoms. This is most probably due to rapid clearance of Fab fragments from circulation that 269 
impedes the neutralization of venom toxins released from the bite site in later stages of the envenoming (Boyer et al., 270 
2013; Gutiérrez et al., 2003; Seifert and Boyer, 2001). In accordance with their intermediate molecular mass, the PK 271 
profile of F(ab´)2-based antivenoms constitutes a middle point between that of IgGs and Fab fragments (Boyer et al., 272 
2013; Gutiérrez et al., 2003; Ho et al., 1990; Isbister et al., 2015; Kurtović et al., 2016; Maung-Maung-Thwin et al., 1988; 273 
Pépin-Covatta et al., 1996; Sevcik et al., 2004). However, in general, due to the heterologous nature of antivenoms 274 
derived from horse or sheep plasma, these antibodies are eliminated faster than expected for a homologous human 275 
antibody (Scherrmann, 1994). The molecular mechanisms behind this observation are not fully understood, but could be 276 
the result of impeded binding to FcRn and/or development of anti-antibodies by the patient’s immune system (Tabrizi et 277 
al., 2006; Wang et al., 2008). 278 
While information on animal plasma-derived antivenom PK is somewhat available, only two studies have reported 279 
the PK profiles of recombinant antibody fragments targeting animal toxins. Aubrey et al. investigated the in vivo 280 
kinetics of a homodimeric diabody (50 kDa) derived from the anti-AahI murine 9C2 antibody after intraperitoneal 281 
injection into mice (Aubrey et al., 2003). The diabody displayed rapid diffusion, being detected in plasma only 5 min 282 
after its administration. Consequently, the maximum concentration (Cmax) was reached shortly after (30-60 min 283 
post-injection). High concentrations (> 50% Cmax) were detected for at least 6 h, and complete clearance of the diabody 284 
took approximately 24-32 h (Aubrey et al., 2003). In the other study, Hmila et al. compared the distribution and kinetics 285 
of two nanobodies (NbAahIF12 and NbAahII10, 14 kDa each) and a bispecific nanobody construct (NbF12-10, 29 kDa) 286 
to those of a F(ab´)2-based (~110 kDa) scorpion antivenom after intravenous administration in mice and rats (Hmila et 287 
al., 2012). In vivo monitoring of radiolabeled nanobodies and F(ab´)2 fragments revealed that the nanobody-based 288 
molecules were cleared from blood faster than the F(ab´)2 antivenom, most likely due to the lower molecular mass of 289 
nanobodies. Additionally, a major difference was observed in the organ accumulation of the antitoxins. Monovalent 290 
nanobodies and the bispecific construct accumulated mainly in the kidneys, whereas F(ab´)2 fragments were 291 
predominantly retained in the liver (Hmila et al., 2012). 292 
PD has implications on PK profiles of antibodies, and this will further have implications on the efficacy, which 293 
highlights the importance of choosing the right antibody format for rational development of novel antivenoms. Often, 294 
venoms consist of complex mixtures containing both low and high molecular mass toxins, acting locally and/or 295 
systemically. On one hand, antivenoms should ideally provide antitoxins able to rapidly reach locally acting toxins and 296 
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toxins that reach systemic extravascular targets very fast, such as low molecular mass neurotoxins. On the other hand, 297 
antivenoms should also provide antitoxins with extended half-lives that remain in circulation for prolonged periods of 298 
time (many hours to days). This will allow the antitoxins with long half-lives to intercept and neutralize systemically 299 
acting toxins in the circulatory system before these toxins reach their target site (Gutiérrez et al., 2003). Thus, an 300 
antivenom comprised of a mixture of different antibody formats could be necessary to target all medically relevant 301 
toxins present in complex venoms (Gutiérrez et al., 2003). Regarding the route of administration, notable differences 302 
have been found when comparing intravenous administration with intramuscular administration. Intravenous injections 303 
directly deliver the antibodies to the bloodstream, avoiding the absorption step and providing complete bioavailability 304 
(Liu, 2017). Hence, it is considered the preferred route of administration for antivenoms in a hospital setting. On the 305 
other hand, intramuscularly injected antivenoms have shown poor efficacy due to slow absorption and reduced 306 
bioavailability of the antibodies or their fragments (Geoffrey K Isbister et al., 2008; Pépin-Covatta et al., 1996, 1995; 307 
Hilda Vázquez et al., 2010). Nevertheless, it could still be considered an option, as antivenoms are occasionally required 308 
to be administered in the field (Warrell, 1995). Although the PK of a specific antibody format may be predicted based 309 
on the general distribution and elimination characteristics typical for its molecular mass, more PK studies are required 310 
to increase the current knowledge and guide the development of recombinant antivenoms based on in-depth 311 
understanding of the PK-PD relationship of each antibody format on an individual case basis. Additionally, favorable 312 
PK-PD for a given antibody format may very well depend on the toxicokinetics of the target toxin(s). 313 
 314 
4. Propensity for adverse reactions of different antibody formats 315 
Adverse reactions to animal plasma-derived antivenoms are relatively common, with 6-59% of patients 316 
experiencing early-onset reactions, depending on the particular antivenom being used. In rare cases, administration of 317 
animal plasma-derived antivenoms may result in severe life-threatening anaphylaxis (Schaeffer et al., 2012; Stone et al., 318 
2013). Further, 5-23% of treated patients experience delayed-onset serum sickness (typically observed 1-2 weeks after 319 
exposure), with symptoms such as high fever, rash, urticaria, and arthralgia (LoVecchio et al., 2003). The propensity of 320 
an animal-derived antivenom to generate early and late adverse reactions depends on the microbiological and 321 
physicochemical quality of the product, its format (i.e. Fab, F(ab’)2, or IgG), and the total amount of protein injected in 322 
a treatment (León et al., 2013). A relatively low rate of early adverse reactions (~5-7%) has been reported for a highly 323 
purified Fab antivenom in use in the USA, which includes an affinity chromatography purification step in its 324 
manufacture (Cannon et al., 2008; Farrar et al., 2012). On the other hand, F(ab’)2 and IgG antivenoms of good 325 
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physicochemical quality induce early adverse reactions in 13 to 26% of treated patients (see review by (León et al., 326 
2013)). In these cases, the majority of such reactions are mild, including mostly cutaneous manifestations. In contrast, 327 
other antivenoms of poor physicochemical quality, or containing pyrogens, are known to induce a rate of adverse 328 
reactions as high as 80%, with some of these reactions being severe (León et al., 2013). Most early adverse reactions to 329 
antivenoms are de novo reactions, i.e. occurring in people who have not been previously sensitized with antivenoms and 330 
are, therefore, non-IgE-mediated. In fact, only a small proportion of early adverse reactions are IgE-mediated (León et 331 
al., 2013). 332 
Administration of animal-derived antivenoms also induce late adverse reactions, a type III hypersensitivity 333 
phenomenon associated with serum sickness (León et al., 2013). This occurs approximately 1-2 weeks after antivenom 334 
infusion as a consequence of the generation of human antibodies against animal IgGs, and the consequent formation of 335 
antigen-antibody complexes, which exert effects in the microvasculature and the joints, causing arthralgia, fever, and 336 
urticaria (Gutiérrez et al., 2017a). The incidence of serum sickness after antivenom administration has not been analyzed 337 
in depth, although it seems to depend on the total load of foreign protein administered (LoVecchio et al., 2003) and on 338 
the format of the antivenom preparation. In particular, Fab antivenoms have been shown to induce a much lower 339 
incidence of serum sickness than IgG and F(ab’)2 antivenoms (Lavonas et al., 2013; León et al., 2013). A detailed 340 
account of the studies reporting incidences of adverse reactions to animal-derived antivenoms can be found in Table 1 341 
(León et al., 2013). 342 
There are no antivenoms in clinical use that are made of monoclonal antibodies or of any type of recombinant 343 
product. Information on safety of other biotherapeutics based on monoclonal antibodies may instead be utilized to shine 344 
light on the potential challenges that recombinant antivenoms may face, when they become available in the future. 345 
Murine monoclonal antibodies have been shown to induce early and late adverse reactions in humans (see reviews by 346 
Descotes (Descotes, 2009) and Hansel et al. (Hansel et al., 2010)), owing to their heterologous nature, including 347 
anaphylactic reactions in few cases and serum sickness. As a result, biotherapeutics based on murine antibodies are no 348 
longer put into development and enter clinical trials. The propensity to generate adverse reactions has, however, been 349 
greatly reduced by the generation of chimeric, humanized, and fully human monoclonal antibodies, although it is still 350 
possible to generate anti-idiotype antibodies with such products (Hansel et al., 2010). For example, a humanized 351 
monoclonal antibody against an integrin has been reported to induce early adverse reactions (urticaria) in 4% of patients 352 
(Ransohoff, 2007). Despite these observations, the introduction of humanized or fully human monoclonal antibodies in 353 
the development of new antivenoms is likely to greatly reduce the incidence of early and late adverse reactions, 354 
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currently observed for animal plasma-derived antivenoms, owing to the greater compatibility of these products with the 355 
human immune system (Laustsen, n.d.). Likewise, the fact that antivenoms are usually used only once in a single 356 
individual further reduces the likelihood of development of adverse reactions. From a theoretical viewpoint, it is also 357 
probable that recombinant antivenom antibodies of low molecular mass formats, such as Fab, scFv, VHH, diabodies, 358 
bivalent constructs, and other binding protein formats, will be less prone to induce adverse reactions than whole IgG 359 
preparations. However, this should be carefully balanced with other aspects such as pharmacokinetic profile and the 360 
possible role of the Fc part of the immunoglobulin in its biological action. Finally, optimization of antibody 361 
glycosylation to better resemble human patterns may lead to recombinant antivenom formats with even better 362 
compatibility with the human immune system. All these issues demand renewed research vis-à-vis the current upsurge 363 
in the development of recombinant antivenoms. 364 
 365 
5. Formulation  366 
Owing to the proteinaceous nature of antibodies, antivenoms face many of the generic issues commonly related to 367 
high-protein-concentration solutions. Antivenom antibodies are especially susceptible to degradation when exposed to 368 
heat, freezing, light, pH extremes, shear-stress, agitation, as well as to some metals and organic solvents (Lowe et al., 369 
2011). Particularly heat stability is important for long term storage in tropical regions, where most envenomings occur 370 
(Gutiérrez et al., 2006; Warrell, 2007). Liquid antivenom should generally be stored at 2-8˚C, but this requirement is not 371 
always possible to fulfil in rural areas where the cold-chain is often interrupted or non-existent. When stored at room 372 
temperature, formation of turbidity over time is observed in liquid formulations, indicating physical instability and 373 
decrease in biological activity (Segura et al., 2009). To overcome this issue, many antivenom manufacturers lyophilize 374 
their antivenoms, although this adds to the cost of manufacture (Segura et al., 2009). As an example, two studies on 375 
EchiTAb-Plus-ICP antivenom used to treat snakebite victims in rural sub-Saharan Africa attempted to determine the 376 
optimal state for antivenom stability. These studies indicated that freeze-drying offered the best thermal stability of the 377 
antivenom compared to liquid formulation without stabilizer and liquid formulation stabilized with sorbitol (Herrera et 378 
al., 2017, 2014). Most of the current research efforts are, however, focused on finding a stable liquid formulation that can 379 
be stored at room temperature. As an example Solano et al. (2012) described that an acetate buffered (pH 4.0) formulation 380 
stabilized antivenoms for at least six months at room temperature without the presence of a protective carbohydrate 381 
excipient (Solano et al., 2012). 382 
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Some antivenom formulation additives have been reported to have varying levels of effects depending on the 383 
combination of additive molecules used and on whether the additives are added to liquid or lyophilized formulations. In a 384 
study that compared the stabilizing effects of sorbitol, sucrose, and mannitol in lyophilized antivenom, Herrera et al. 385 
(2014) showed that antivenoms lyophilized with mannitol lost efficacy against the lethal effects of B. asper venom 386 
(Herrera et al., 2014). Furthermore, it was shown that a 5% (w:v) sucrose formulation exhibited the best stability, 387 
indicating that sucrose could perform better as a stabilizer than mannitol and sorbitol in lyophilized antivenoms. Of the 388 
additives used in antivenom formulation, the most commonly used are phenol, cresol, and sodium chloride (see Table 5). 389 
These additives stabilize and preserve the antivenom by preventing aggregation of IgGs and/or antibody fragments, by 390 
providing an isotonic solution, and by having antifungal and bacteriostatic effects (Rodrigues-Silva et al., 1999; Segura et 391 
al., 2009). Preventing aggregation for therapeutic antibodies is crucial, as aggregation may significantly contribute to their 392 
immunogenicity (Rosenberg, 2006; van Beers et al., 2010). 393 
Other less conventional formulations explored at the experimental level focus on enhancing the neutralization 394 
ability through conjugation of protein nanoparticles and/or facilitating the administration through encapsulation. Renu et 395 
al. (2014) used soy protein nanoparticles conjugated to F(ab’)2 fragments to optimize the neutralizing effects of Bungarus 396 
caeruleus antivenom (Renu et al., 2014). They achieved to produce the smallest size of self-stabilized soy protein 397 
nanoparticle reported within antivenom research, which displayed improved neutralization capacity against toxins from 398 
B. caeruleus venom at a much lower concentration compared to the non-conjugated antivenom. The conjugated 399 
antivenom particles also showed enhanced thermal stability (Renu et al., 2014). 400 
Certain formulations could allow for alternative routes of antivenom administration. These formulations are being 401 
explored to allow non-physicians to aid snakebite victims before the victim reaches a clinic or hospital. Currently, all 402 
antivenoms are administered by intravenous bolus injection and/or intravenous infusion (Ahmed et al., 2008). Compared 403 
to other common routes of administration (e.g. intramuscular route), intravenous injection offers the fastest route to 404 
maximum concentration of antivenom in the circulatory system (Gutiérrez et al., 2003), although rapid infusion of foreign 405 
antivenom proteins may result in adverse reactions often experienced by patients upon antivenom administration (León et 406 
al., 2013). An approach to minimize the adverse effects of antivenom, that has only been explored once experimentally, 407 
involves oral administration of alginate encapsulated antivenom (Bhattacharya et al., 2014). However, even if antibodies 408 
can be properly formulated for oral administration, oral delivery of an emergency medicine will come at a cost to 409 
bioavailability and the delayed arrival of antibodies may not be optimal for efficient toxin neutralization. Thus, even if 410 
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such formulations may one day be useful in the field, they will have to be supplemented with intravenously (i.v.) 411 
administered antivenom once the snakebite victim reaches a clinic or hospital. 412 
In conclusion, it is observed that the majority of antivenoms currently on the market are formulated with one or 413 
more of the excipients phenol, cresol, sodium chloride, glycine in some products and, in the case of freeze-dried 414 
antivenoms, sucrose. Most of the available data on antivenom formulation is based on plasma-derived equine or ovine 415 
polyclonal F(ab’)2s, possibly due to the early stage of development for recombinant antivenoms based on monoclonal 416 
antibodies. It seems likely that antivenom research will increasingly focus on more modern approaches involving the use 417 
of recombinant human antibodies (Laustsen, n.d.; Laustsen et al., 2017). With such a shift, more research is needed in 418 
order to develop and optimize formulations of mixtures of monoclonal antibodies. These future efforts will fortunately not 419 
start from scratch. In other fields, (mixtures of) human monoclonal antibodies have been extensively used, and existing 420 
formulation solutions from these fields are likely to also be applicable for recombinant antivenoms (Heijtink et al., 1999; 421 
Robak et al., 2012) 422 
 423 
Table 5. Different formulations used for antivenoms 424 
Trade name Format Formulation Additive molecule Benefit of additive References 
Studies performed on antivenom formulation 
 Ovine Fab
 
Liquid Acetate buffer 
Buffer and 
stabilization1 
(Al-Abdulla et 
al., 2003) 
 Equine F(ab’)2 Liquid Sorbitol, phenol 
Buffer and 
preservation2 
(Solano et al., 
2012) 
 Equine Lyophilized Sorbitol/Mannitol/Sucrose Stabilization 
(Herrera et al., 
2014) 
 Equine F(ab’)2 Liquid Alginate encapsulation Oral delivery 
(Bhattacharya et 
al., 2014) 
 Equine IgG Liquid 
Phenol, sorbitol, sodium 
chloride 
Preservation, 
protection against heat 
denaturation 
(Segura et al., 
2009) 
 Equine Liquid Phenol/Sorbitol 
Preservation, 
protection against heat 
denaturation 
(Rodrigues-Silv
a et al., 1999) 
 
Equine 
IgG/Equine 
Liquid Sorbitol 
Protection against heat 
denaturation 
(Rodrigues-Silv
a et al., 1997) 
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F(ab’)2 
 Equine F(ab’)2 Liquid Conjugated soy protein NP’s 
Improvement of 
venom neutralization 
efficiency 
(Renu et al., 
2014) 
 mAb Liquid PBS -- 
(Bugli et al., 
2008) 
EchiTAb + ICP Equine IgG 
Liquid/ 
Lyophilized 
Sorbitol/sucrose 
Stabilization, 
protection against heat 
denaturation 
(Herrera et al., 
2017) 
Snake antivenoms currently on market with disclosed formulation 
ViperaTAb Equine F(ab’)2 Liquid Sodium acetate buffer Buffer 
(“Product 
information. 
ViperaTAb.,” 
n.d.) 
Snake Antivenin 
(Polyvalent) I.P. 
Equine Liquid Phenol Preservation 
(“Product 
information. 
Snake 
Antivenin 
(Polyvalent) 
I.P.,” n.d.) 
Snake Venom Antiserum 
I.P. 
Equine Liquid Cresol Preservation 
(“Product 
information. 
Snake Venom 
Antiserum I.P.,” 
n.d.) 
Anavip Equine F(ab’)2 Lyophilized 
Sodium chloride, sucrose, 
glycine 
Stabilization 
(“Product 
information. 
Anavip.,” n.d.) 
CroFab Ovine Fab Lyophilized PBS Buffer 
(“Crofab 
(Crotalidae 
Polyvalent 
Immune Fab 
Ovine),” n.d.) 
Suero Antiofidico 
polivalente 
Equine F(ab’)2 Liquid Phenol, sodium chloride Preservation 
(“Suero 
Antiofidico 
polivalente. 
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Centro de 
Biotechnologia 
Facultad de 
Farmacia.,” 
n.d.) 
Black Snake Antivenom Equine F(ab’)2 Liquid Phenol, sodium chloride Preservation 
(“Product 
information. 
Black Snake 
Antivenom.,” 
n.d.) 
Brown Snake Antivenom Equine F(ab’)2 Liquid Phenol, sodium chloride Preservation 
(“Product 
information. 
Brown Snake 
Antivenom.,” 
n.d.) 
Death Adder Antivenom Equine F(ab’)2 Liquid Phenol, sodium chloride Preservation 
(“Product 
information. 
Death Adder 
Antivenom.,” 
n.d.) 
Polyvalent Snake 
Antivenom 
Equine F(ab’)2 Liquid Phenol, sodium chloride Preservation 
(“Product 
information. 
Polyvalent 
Snake 
Antivenom.,” 
n.d.) 
Sea Snake Antivenom Equine F(ab’)2 Liquid Phenol, sodium chloride Preservation 
(“Sea Snake 
Antivenom - 
Current 
Consumer 
Medicine 
information.,” 
n.d.) 
Taipan Antivenom Equine F(ab’)2 Liquid Phenol, sodium chloride Preservation 
(“Taipan 
Antivenom - 
Curent 
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Consumer 
Medicine 
information 
Nov 2017.,” 
n.d.) 
Tiger Snake Antivenom Equine F(ab’)2 Liquid Phenol, sodium chloride Preservation 
(“Tiger Snake 
Antivenom - 
Current 
Consumer 
Medicine 
Information Oct 
2016.,” n.d.) 
Soro Antielapídico 
(bivalente) 
Equine F(ab’)2 Liquid Phenol, sodium chloride Preservation 
(“Product 
information. 
Soro 
Antielapidico 
(bivalente).,” 
n.d.) 
Soro Antibotrópico 
(pentavalente) e 
Antilaquético 
Equine F(ab’)2 Liquid Phenol, sodium chloride Preservation 
(“Product 
information. 
Soro 
Antibotropico 
(pentavalente) e 
antilaquetico.,” 
n.d.) 
Soro Anticrotálico Equine F(ab’)2 Liquid Phenol, sodium chloride Preservation 
(“Product 
information. 
Soro 
Anticrotálico.,” 
n.d.) 
Soro Antibotrópico 
(pentavalente) e 
Anticrotálico 
Equine F(ab’)2 Liquid Phenol, sodium chloride Preservation 
(“Product 
information. 
Soro 
antibotropico 
(pentavalente) e 
anticrotalico.,” 
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n.d.) 
Soro Antibotrópico 
(pentavalente) 
Equine F(ab’)2 Liquid Phenol Preservation 
(“Product 
information. 
Soro 
Antibotropico 
(pentavalente).,
” n.d.) 
Suero Antibotrópico 
polivalente 
Equine IgG Liquid Phenol, thimerosal Preservation 
(Biológicos et 
al., n.d.) 
Suero Anticrotálico 
monovalente 
Equine IgG Liquid Phenol, thimerosal Preservation 
(Biológicos et 
al., n.d.) 
Suero Antilachésico 
monovalente 
Equine IgG Liquid Phenol, thimerosal Preservation 
(Biológicos et 
al., n.d.) 
Suero Antiloxoscélico 
monovalente 
Equine F(ab’)2 Liquid Phenol, thimerosal Preservation 
(Biológicos et 
al., n.d.) 
EchiTAbG antivenom Ovine IgG Liquid PBS Buffer 
(Casewell et al., 
2010) 
EchiTAb-Plus-ICP Equine IgG Liquid Phenol, sodium chloride Preservation, 
(Segura et al., 
2010) 
Banded Krait Antivenin Equine IgG Lyophilized 
Glycine, phenol, sodium 
chloride 
Preservation, stabilizer 
(“Product 
information. 
Banded Krait 
Antivenin.,” 
n.d.) 
Viper Venom Antitoxin Equine IgG Liquid Phenol, sodium chloride Preservation 
(“Product 
information. 
Viper Venom 
Antitoxin.,” 
n.d.) 
Snake Venom Antiserum Equine F(ab’)2 Lyophilized 
Cresol, glycine, sodium 
chloride 
Preservation, stabilizer 
(“Premium 
Serums. Snake 
Venom 
Antiserum - 
Lyophilized.,” 
n.d.) 
Snake Venom Antiserum Equine F(ab’)2 Liquid Cresol, glycine, sodium Preservation, stabilizer (“Premium 
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I.P chloride Serums. Snake 
Venom 
Antiserum I.P.,” 
n.d.) 
Snake Venom Antiserum 
(Central Africa) 
Equine F(ab’)2 Lyophilized 
Cresol, glycine, sodium 
chloride 
Preservation, stabilizer 
(“Premium 
Serums. Snake 
Venom 
Antiserum 
(Central 
Africa).,” n.d.) 
Snake Venom Antiserum 
(Pan Africa) 
Equine F(ab’)2 Lyophilized 
Cresol, glycine, sodium 
chloride 
Preservation, stabilizer 
(“Premium 
Serums. Snake 
Venom 
Antiserum (Pan 
Africa).,” n.d.) 
Snake Venom Antiserum 
(African – Ten) 
Equine F(ab’)2 Lyophilized 
Cresol, glycine, sodium 
chloride 
Preservation, stabilizer 
(“Premium 
Serums. Snake 
Venom 
Antiserum 
(African - 
Ten).,” n.d.) 
Snake Venom Antiserum 
(North Africa) 
Equine F(ab’)2 Lyophilized 
Cresol, glycine, sodium 
chloride 
Preservation, stabilizer 
(“Premium 
Serums. Snake 
Venom 
Antiserum 
(North 
Africa).,” n.d.) 
Scorpion antivenoms currently on market with disclosed information 
Scorpion Venom 
Antiserum (India) 
Equine F(ab’)2 Lyophilized 
Cresol, glycine, sodium 
chloride 
Preservation, stabilizer 
(“Premium 
Serums. 
Scorpion 
Venom 
Antiserum 
(India).,” n.d.) 
Scorpion Venom 
Antiserum (North Africa) 
Equine F(ab’)2 Lyophilized 
Cresol, glycine, sodium 
chloride 
Preservation, stabilizer 
(“Premium 
Serums. 
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Scorpion 
Venom 
Antiserum 
(North 
Africa).,” n.d.) 
Suero antiescorpiónico Equine F(ab’)2 Liquid Phenol, sodium chloride 
Preservation, 
stabilization 
(“Suero 
antiescorpiónic
o. Centro de 
Biotechnologia 
Facultad de 
Farmacia.,” 
n.d.) 
Alacramyn Equine Fab Lyophilized Cresol Preservation 
(“Instructions 
for use. 
Alacramyn®.,” 
n.d.) 
Soro antiarachnidico Equine F(ab’)2 Liquid Phenol Preservation 
(“Package 
leaflet: Soro 
antiarachnidico 
- Butantan.,” 
n.d.) 
Soro antiescorpiônico Equine F(ab’)2 Liquid Phenol Preservation 
(“Package 
leaflet: Soro 
antiescorpionic
o - Butantan.,” 
n.d.) 
Polyvalent Scorpion 
Antivenom 
Equine F(ab’)2 Liquid Cresol, PBS Preservation 
(“Polyvalent 
Scorpion 
Antivenom | 
National 
Antivenom and 
Vaccine 
Production 
Center.,” n.d.) 
Scorpifav Equine F(ab’)2 Liquid 
Sodium chloride, polysorbate 
80 
Preservation 
(“MAVIN 
Poison Centre 
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Munich - 
Scorpifav.,” 
n.d.) 
Scorpion Venom 
Antiserum 
Equine IgG Lyophilized Ortho-cresol Preservation 
(“Scorpion Anti 
Serum | VINS 
BioProducts 
Limited,” n.d.) 
Soro Antiescorpiônico 
(FUNED) 
Equine F(ab’)2 Liquid Phenol, sodium chloride Preservation 
(“Product 
information. 
Soro 
Antiescorpiônic
o (FUNED).,” 
n.d.) 
Anti-scorpion Venom 
Serum 
Equine IgG Lyophilized Phenol Preservation 
(“Antitoxins & 
Sera: 
Antiscorpion 
venom serum,” 
n.d.) 
Spider antivenoms currently on market with disclosed information 
Funnel Web Spider 
Antivenom 
Leporid IgG Lyophilized 
Glycine, sodium chloride, 
sodium phosphate – dibasic, 
sodium phosphate - 
monobasic 
Preservation, 
stabilization 
(“Funnel Web 
Spider 
Antivenom - 
Current 
Cunsumer 
Medicine 
Information Jan 
2017.,” n.d.) 
Red Back Spider 
Antivenom 
Equine IgG Liquid Phenol, sodium chloride Preservation 
(“Red Back 
Spider 
Antivenom - 
Current 
Consumer 
Medicine 
Information 
Febr 2017.,” 
n.d.) 
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Aracmyn PLUS Equine F(ab’)2 Lyophilized Cresol Preservation 
(“Aracmyn Plus 
- Bioclon | PR 
Vademecum 
Mexico,” n.d.) 
Reclusmyn Equine F(ab’)2 Lyophilized Cresol Preservation 
(“Our Products - 
Reclusmyn.,” 
n.d.) 
Soro antiarachnidico Equine F(ab’)2 Liquid Phenol Preservation 
(“Package 
leaflet: Soro 
antiarachnidico 
- Butantan.,” 
n.d.) 
Suero antiloxoscélico 
monovalente 
Equine IgG Liquid Thimerosal, phenol Preservation 
(“Detalle del 
Producto. Suero 
antiloxoscélico 
monovalente.,” 
n.d.) 
Soro Antilatrodéctico Equine F(ab’)2 Liquid Phenol, sodium chloride Preservation 
(“Instituto Vital 
Brazil - Soro 
Antilatrodéctico
.,” n.d.) 
Antivenin (Latrodectus 
mactans) 
Equine IgG Lyophilized Thimerosal Preservation 
(“Antivenin 
(Latrodectus 
mactans).,” 
n.d.) 
1Stabilization implies benefits that prevent aggregation of IgGs and/or IgG fragments. 425 
2Preservation implies antifungal and bacteriostatic benefits. 426 
 427 
6. Expression of different antibody formats 428 
To enable large-scale production of novel antivenoms consisting of recombinant antibodies or antibody fragments, 429 
a suitable expression system is essential. To the best of our knowledge, so far, no antibody nor antibody fragment 430 
targeting an animal toxin has been produced in larger scale. Several different research efforts have, however, employed 431 
different expression hosts, which will be reviewed in the following for their suitability for Research and Development 432 
(R&D) purposes and scale up. 433 
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 434 
6.1. Key differences between eukaryotes and prokaryotes in antibody expression 435 
Antibodies and antibody fragments can be expressed in either prokaryotic or eukaryotic cells, depending on the 436 
structure of the protein product and the application of the desired antibody fragment. These cell types are inherently 437 
different and thus offer different advantages and disadvantages in relation to antibody expression (Berlec and Strukelj, 438 
2013).  439 
Advantages of prokaryotic expression of antibodies include low cost of media and ease of handling. For these 440 
reasons, E. coli has been a much-used organism for expression of several different antibody formats within antivenom 441 
research. However, the inability of prokaryotes to glycosylate antibodies limits the range of antibody formats that can 442 
be expressed with these systems, therefore E. coli has mainly been used to produce diabodies, scFvs, Fabs, and VHHs 443 
(see Table 6). Furthermore, the tendency to form incorrectly folded proteins and insoluble aggregates in the reducing 444 
environment of the bacterial cytoplasm decreases expression yields. Other prokaryots that are more promising than E. 445 
coli for production of biotherapeutics could be strains of the genus Bacillus, which have a long track record of 446 
successful use for expression of both heterologous and homologous proteins (Lakowitz et al., 2017). These have, 447 
however, not yet been employed within the field of antivenom. 448 
In contrast to prokaryotic cells, mammalian cells are capable of performing more advanced post-translational 449 
modifications, such as glycosylation, and possess more complex cellular machinery for folding and secretion (Chadd 450 
and Chamow, 2001; Frenzel et al., 2013). Mammalian cells are capable of yielding more diverse antibody formats with 451 
lower immunogenicity (Chadd and Chamow, 2001; Frenzel et al., 2013) and are the primary production system for full 452 
IgG molecules (Walsh, 2014). Also, mammalian cells typically deliver close to 100% fully functional proteins, in 453 
contrast to prokaryotic expression systems, where the yield of active protein may be significantly lower than the overall 454 
protein yield. However, drawbacks for mammalian cells include high cost of media and consumables, difficulty in 455 
handling, and (arguably) slow growth rate. Productivity has, however, been increased significantly in recent decades by 456 
optimization of protein expression levels for many of the mammalian cell lines employed in industrial processes, which 457 
compensates for the slower growth of mammalian cells compared to prokaryotes. Previously, pathogenic 458 
contaminations of cell cultures also posed a threat, but modern protocols for avoiding such contaminations limit this 459 
issue (Frenzel et al., 2013). 460 
 461 
6.2. scFvs are typically expressed in E. coli 462 
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The use of E. coli as an expression host appears to be the most commonly used system within antivenom research, 463 
not only for scFvs, but also for other antibody fragments (see Table 6). In 1999, Mousli et al. expressed an scFv in E. 464 
coli. capable of neutralizing the AahII toxin of the desert scorpion Androctonus australis hector (Mousli et al., 1999). 465 
More recently, scFv expression in E. coli cells has been optimized, leading to improved expression yields. As an 466 
example, signal peptides that localise antibody fragments to the oxidative environment of the periplasm are often added 467 
to the expression plasmid (Amaro et al., 2011; Juárez-González et al., 2005; Juste et al., 2007; Pucca et al., 2012; 468 
Roncolato et al., 2013). The oxidative environment allows for the formation of disulphide bond, which is normally 469 
unattainable in the reducing cytoplasmic environment of E. coli, wherein expression tends to lead to non-functional 470 
aggregates. Research groups outside of the field of antivenom have attempted different strategies as alternatives to 471 
localising antibodies to the periplasm to achieve a higher degree of correct folding. These strategies include: (i) 472 
denaturation and refolding of cytoplasmic, aggregated antibodies, (ii) increased expression of cytoplasmic chaperones 473 
in addition to altering the cytoplasmic environment by creating mutations in reductases, (iii) creating cysteine-free 474 
antibodies, and (iv) cytoplasmic oxidase expression (Frenzel et al., 2013; Gaciarz et al., 2016; Veggiani and De Marco, 475 
2011). These methods have been employed with varying degrees of success. Denaturation and refolding does often not 476 
prove efficient, whereas increasing the expression of chaperones and cytoplasmic oxidases have successfully increased 477 
yields for Fab and VHH fragments, respectively (Frenzel et al., 2013; Gaciarz et al., 2016). 478 
Engineering of expression vectors, such as optimization of codons, promotor, Shine-Dalgarno sequence, leader 479 
sequence, and transcript stability, can further improve scFv expression in E. coli (Frenzel et al., 2013). Furthermore, 480 
cultivation of E. coli in bioreactors instead of shake flasks has in some cases significantly increased scFv yields. As an 481 
example of shake flask cultivation, Kipriyanov et al. obtained a yield of 16.5 mg/L for an scFv against the T cell surface 482 
antigen CD3 by expression in E. coli cultivated in shake flasks after optimization (Kipriyanov et al., 1997). By 483 
comparison, Sletta et al. obtained a much higher yield of 1.2 g/L for the same scFv after optimization by using 484 
bioreactor production (Kipriyanov et al., 1997; Sletta et al., 2004). Nevertheless, bioreactor production may not 485 
generally be superior to shake flask production, and examples of high scFv expression yields when using shake flasks 486 
also exist. For instance, Gaciarz and colleagues were able to obtain yields of 240 mg/L for an scFv by shake flask 487 
cultivation of E. coli (Gaciarz et al., 2016).  488 
 489 
6.3. Fabs are typically expressed in E. coli  490 
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Within antivenom research, Fabs have primarily been produced in E. coli strains (Table 6). Many of these strains 491 
have been engineered to circumvent problems inherent to expression of mammalian proteins in prokaryotic cells. As an 492 
example, E. coli strains have been modified to compensate for the limited availability of tRNAs corresponding to 493 
codons infrequently used in prokaryotes, but frequently used in eukaryotes. Bugli et al. tested such an E. coli strain and 494 
found that increasing the intracellular availability of tRNAs with anticodons for AGG, AGA, AUA, CUA, CCC, and 495 
GGA also increased yields of their Fab directed against alpha-latrotoxin from the venom of L. tredecimguttatus 496 
(Mediterranean black widow) from 0.5 mg/L to 1.5 mg/L (Bugli et al., 2008).  497 
Optimization of growth media and additives, timing and duration of induction, concentration of reactants used for 498 
induction, and other parameters may dramatically increase antibody expression yields (Kipriyanov et al., 1997; Selisko 499 
et al., 2004; Ukkonen et al., 2013). Although still in the lower range of yields, this is demonstrated by a study of a Fab 500 
capable of neutralizing whole venom antigens of the C. noxius scorpion, in which Fab yields were increased by a factor 501 
of 20 (from 0.05 mg/L to 1 mg/L) through optimisation of addition of sucrose to the medium, temperature and timing of 502 
induction, and concentration of the induction agent (Selisko et al., 2004). In the same study, Selisko and colleagues also 503 
found that lowering the temperature of induction in their case had a profound positive impact on the yield of 504 
biologically active protein, as this reduced the number of insoluble, cytoplasmic aggregates (Selisko et al., 2004). 505 
Conversely, however, Aubrey et al. found that inducing expression at low temperatures resulted in extensive 506 
cytoplasmic aggregation and low Fab yields (Aubrey et al., 2004). This demonstrates that the temperature of induction 507 
is of paramount importance for correct folding, but that the optimal temperature may be different from case to case.  508 
Similar to scFvs, Fabs are often localised to the periplasm to promote disulphide bond formation and ameliorate 509 
aggregations (Aubrey et al., 2004; Bugli et al., 2008; Selisko et al., 2004). An alternative solution to periplasmic 510 
expression from outside the field of antivenom is introduction of enzymes (e.g. protein disulphide isomerase) 511 
facilitating disulphide bond formation in the cytoplasm, as used by Gaciarz and colleagues for Fab expression (Gaciarz 512 
et al., 2016). Thus, it is important to consider in which cellular space the Fab fragment should be localized to achieve 513 
the highest possible yield. 514 
 515 
6.4. Diabodies and VHHs are expressed in E. coli 516 
E. coli is also a widely employed expression host for diabodies (Aubrey et al., 2003; di Tommaso et al., 2012; 517 
Rodríguez-Rodríguez et al., 2012) and VHHs (Abderrazek et al., 2009; Chavanayarn et al., 2012; Hmila et al., 2012, 2010, 518 
2008; Richard et al., 2013; Stewart et al., 2007), which similarly to scFvs and Fabs are often targeted to the periplasm to 519 
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promote disulphide bond formation and proper folding (Abderrazek et al., 2009; Aubrey et al., 2003; di Tommaso et al., 520 
2012; Hmila et al., 2010, 2008; Richard et al., 2013). Diabodies and VHHs have been developed against toxins from 521 
snakes and, to a slightly greater extent, scorpions, whereas to the best of our knowledge, no diabodies nor VHHs have 522 
been directed towards spider toxins. Specifically, three VHH studies all focused on two different N. kaouthia (cobra) 523 
toxins (Chavanayarn et al., 2012; Richard et al., 2013; Stewart et al., 2007), while one study describes diabodies directed 524 
against C. noxius (scorpion) venom antigens (Rodríguez-Rodríguez et al., 2012), and six studies (two diabody studies 525 
and four VHH studies) were all concerned with antibodies directed against AahI and AahII toxins from A. australis 526 
hector (scorpion) venom (Abderrazek et al., 2009; Aubrey et al., 2003; di Tommaso et al., 2012; Hmila et al., 2012, 2010, 527 
2008).  528 
 529 
6.5. IgGs are expressed in mammalian hybridoma cell lines within antivenom R&D  530 
Although aglycosylated IgGs have been produced in E. coli cells (Frenzel et al., 2013), a much more commonly 531 
employed expression organism for IgGs for research use is hybridoma cells. Hybridomas are generated by fusion of 532 
antibody-producing, mammalian, B lymphocytes (typically murine cells) from immunized animals and an immortalized 533 
cell line of choice. Hybridomas thus present advantages and disadvantages, making them suited for R&D purposes, but 534 
less suited for large-scale production. As their most relevant feature, they are immortalised and capable of antibody 535 
production. Antibody expression in hybridoma cells has been extensively used within the field of antivenoms, as 536 
illustrated by Table 6, especially for the IgG format, partially due to the difficulty of expressing functional versions of 537 
the IgG format in prokaryotes. In 2008, Morine and colleagues produced two IgGs capable of neutralizing both the 538 
haemorrhagic and proteolytic activities of the snake venom metalloproteinase Hr1a (Morine et al., 2008). These IgGs 539 
were produced by hybridomas cultivated in vitro and harvested from the culture supernatant (Morine et al., 2008). 540 
Others have followed similar procedures for expression of toxin-neutralizing IgGs (Bahraoui et al., 1988; Jia et al., 541 
2000). Another approach entails in vivo production and harvest of IgGs from ascitic fluids (Alvarenga et al., 2005, 2003; 542 
Boulain et al., 1982; Clot-Faybesse et al., 1999; Frauches et al., 2013; Licea et al., 1996; Li et al., 1993; Lomonte et al., 543 
1992; Lomonte and Kahan, 1988; Masathien et al., 1994; Perez et al., 1984; Stiles et al., 1994; Trémeau et al., 1986; 544 
Fernando Zamudio et al., 1992). Several reasons for favouring this approach exist for research purposes. Some 545 
hybridoma cell lines do not grow well in vitro, and purification of IgAs, IgMs, and IgG3s from in vitro cultures may 546 
result in denaturation and consequent loss of activity (Ward et al., 1999). Thus, if high antibody concentrations and 547 
activity levels are needed for preliminary studies and a small degree of impurity is permissible, growing hybridomas 548 
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inside the peritoneal cavity of mice may be preferable to cultivation in conventional medium for research application 549 
(Ward et al., 1999). Hybridomas cultured in vitro have in some cases been shown to produce alternatively glycosylated 550 
IgGs relative to those produced by hybridomas in vivo, affecting their antigen-binding capacities (Ward et al., 1999). 551 
Thus, it may be important to investigate glycosylation patterns when going from in vitro to in vivo.  552 
Although hybridomas have historically been used extensively for expression of antibodies within many fields, 553 
these cell lines have several restraints for upscaling. These restraints include poorly defined nutrient needs of these cell 554 
types, accumulation of toxic metabolites, high oxygen demand, and fragility of the cells (Randerson, 1985). The 555 
problem of chromosomal instability is also inherent to long-term expression in many cell lines, such as hybridomas, 556 
non-secreting murine myeloma (NS0) cells, and human embroyonic kidney (HEK) cells, and overgrowth by 557 
nonproducing cells constitutes another potential problem (Randerson, 1985). 558 
 559 
6.6. Organisms well suited for large-scale production of antibodies and antibody fragments 560 
Antibodies and antibody fragments are the fastest growing class of biopharmaceuticals (Pucca et al., 2011). Most 561 
of the organisms described above are suited for R&D purposes, but have their limitations when it comes to large-scale 562 
production. These limitations include the propensity for producing endotoxins and the restricted number of formats that 563 
can produced in E. coli and the low cost-efficiency and difficulty of upscaling for hybridoma cell lines. 564 
From a quantitative perspective, microbial cell lines, and E. coli lines in particular, are responsible for the 565 
production of the majority of approved biotherapeutics (Walsh, 2014). However, they are not responsible for the 566 
production of the majority of approved therapeutic antibodies, which may be due to the inability of microbial cell lines 567 
to provide correct human glycosylation of antibodies (Ecker et al., 2015; Walsh, 2014). Furthermore, microbial cell 568 
lines often attain low yields due to incorrect folding and formation of aggregates (Chadd and Chamow, 2001). Another 569 
disadvantage of E. coli and other gram-negative bacteria is that they produce endotoxins, which may compromise 570 
safety, if they are not properly removed. While efforts have been made to produce endotoxin-free E. coli strains for 571 
recombinant protein production (Mamat et al., 2015), no antibodies produced in E. coli have been approved by the Food 572 
and Drug Administration (FDA) or European Medicines Agency (EMA) since 2009 and 2008, respectively (ACTIP, 573 
2017).  574 
For production of therapeutic antibodies, mammalian cell lines are often chosen as the expression organism 575 
(Berlec and Strukelj, 2013; Wurm, 2004). Mammalian cell lines were responsible for production of 95% of approved 576 
therapeutic antibodies in 2013 (Jäger et al., 2013) and for the production of 29 out of 30 (96.7%) approved therapeutic 577 
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antibodies in 2014 (Walsh, 2014). By comparison, E. coli was only responsible for the production of one of these 578 
antibodies in 2014 (Walsh, 2014). One of the popular mammalian expression hosts for therapeutic proteins is the 579 
Chinese Hamster Ovary (CHO) cell. In 2014, CHO cells alone were responsible for the production of 35.5% of all 580 
approved biotherapeutics (Walsh, 2014). Although CHO cells are the most commonly used mammalian cell lines for 581 
IgG production, other cell lines (e.g. NS0, HEK, and hybridoma lines) are also used (Chadd and Chamow, 2001; 582 
Frenzel et al., 2013). Figure 8 shows a schematic representation of mammalian cell production of IgGs. 583 
Finally, antibodies have also been expressed in other gram-negative bacteria (in addition to E. coli), gram-positive 584 
bacteria, various yeast strains, fungi, protozoa, insect cells, additional mammalian cell lines, transgenic plants, and even 585 
transgenic animals (Chadd and Chamow, 2001; Frenzel et al., 2013). Recently, a recombinant antivenom made in 586 
transgenic plants expressing various camelid antibodies against toxins of the venom of Bothrops asper was described 587 
(Julve Parreño et al., 2017). Several of the aforementioned production hosts are in use for large-scale production of 588 
biotherapeutics (Walsh, 2014), while others are still in the process of procedure optimization for future large-scale 589 
production. Given their regulatory success and the efforts put into strain development and genetic engineering in other 590 
fields, it seems likely, though, that the CHO cell will be the main expression organism for antibodies in most 591 
therapeutic areas – particularly full IgGs. 592 
 593 
6.7. Practical considerations for production of recombinant antivenoms 594 
In addition to production cost, factors to consider when choosing a manufacturing strategy for (mixtures of) 595 
antibodies and antibody fragments for recombinant antivenoms, include i) the therapeutic benefits of the specific 596 
antibody format (different formats have different PK-PD and are suitable for different purposes), ii) the importance of 597 
(proper) glycosylation, iii) ease of purification, iv) history of regulatory approval, and v) availability of genetic tools for 598 
development of production strains, such as CRISPR (clustered regularly interspaced short palindromic repeats). 599 
Considering these factors, CHO cells or other mammalian cells may possibly be the best choice for large-scale 600 
production of recombinant antivenoms based on more complex antibody formats, such as IgG (Walsh, 2014; Wright 601 
and Morrison, 1997). In regards to cost of treatment, it has been suggested that using CHO cells for oligoclonal 602 
expression of mixtures of recombinant human IgGs could provide an entire treatment against a typical snakebite 603 
envenoming for as little as USD 30-350 (Laustsen et al., 2017, 2016b). This compares favourably with prices described 604 
by Harrison et al, who report a current market price of an antivenom vial in Kenya ranging from USD 47.9 to USD 315 605 
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(depending on the product), considering that the treatment of a snakebite case usually requires several vials (Harrison et 606 
al., 2017). 607 
 608 
 609 
 610 
 611 
 612 
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Table 6. Expression of antibody formats targeting spider, scorpion, and snake toxins. 613 
Format Origin Expression system Yield Note Reference 
Diabody mixture Human E. coli (strain: TG1) 1.5 mg/L & 2.4 mg/L  (Rodríguez-Rodríguez et 
al., 2012) 
Murine E. coli (strain: 
HB2151) 
  (di Tommaso et al., 
2012) 
0.5 – 0-8 mg/L  (Aubrey et al., 2003) 
Nb/VHH Camelid E. coli (strain: WK6)   (Hmila et al., 2012) 
Camelid (dromedary) 
 
E. coli (strain: WK6) 3.75 mg/L  (Hmila et al., 2010) 
3 mg/L  (Hmila et al., 2008) 
1:15000  (Abderrazek et al., 2009) 
Camelid (camel) E. coli (strain: BL21 
(DE3)) 
 Humanised (Chavanayarn et al., 
2012) 
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Camelid (llama) E. coli (strain: BL21 
(DE3)) 
 Pentamerised (Stewart et al., 2007) 
E. coli (strain: 
HB2151) 
12-18 mg/L. Titre: 
3.0x105 
VhH2-Fc (Richard et al., 2013) 
scFv Human 
 
E. coli (strains: TG1 
and HB2151 E. coli 
non-suppressor 
lineages 
[K12, ara, D(lac-pro), 
thi/F'proA þ Bþ, 
laclqZDM15]) 
1.24x1016  (Pessenda et al., 2016) 
E. coli (strain: 
HB2151) 
3.27x108 CFU/mL  (Tamarozzi et al., 2006) 
0.4 – 0.6 mg/L   (Roncolato et al., 2013; 
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Tamarozzi et al., 2006) 
  (Pucca et al., 2014, 
2012) 
1.3x107 CFU/mL  (Oliveira et al., 2009) 
E. coli (strain: TG1)   (Riaño-Umbarila et al., 
2016) 
1.5 mg/L  (Riaño-Umbarila et al., 
2013) 
1.0 – 2.4 mg/L  (Riaño-Umbarila et al., 
2011) 
0.7 mg/L   (Riaño-Umbarila et al., 
2005) 
  (Rodríguez-Rodríguez et 
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al., 2016) 
  (Cardoso et al., 2000) 
1.0 mg/L  (Amaro et al., 2011) 
E. coli (strains: BL21 
(DE3) & HB2151) 
  (Danpaiboon et al., 
2014; Kulkeaw et al., 
2009) 
Murine E. coli (strain: C43 
(DE3)) 
280 µg/L  (Castro et al., 2014) 
E. coli (strain: TG1) 0.3 – 1.0 mg/L  (Juárez-González et al., 
2005) 
  (Devaux et al., 2001b) 
E. coli (strain: BL21 
(DE3)) 
1 mg/mL after 
purification 
 (Meng et al., 1995) 
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E. coli (strain: 
HB2151) 
  (Mousli et al., 1999) 
E. coli (strain: HB2151 
[K12, ara, ∆(lac-pro), 
thi/F’ proA+ 
B+, laclq lacZ∆M15]) 
0.1 mg/L  Tandem scFv (Juste et al., 2007) 
E. coli (strain: W3110)   (Mérienne et al., 1997) 
Fab  Murine 
 
E. coli (strains: 
XL1-Blue, 
BL21(DE3)pLysS, and 
Rosetta 2(DE3)pLysS) 
0.5 – 1.5 mg/L  (Bugli et al., 2008) 
E. coli (strain: TOPP2) 1 mg/L   (Selisko et al., 2004) 
E. coli (strain: 0.02 mg/L Recombinant (Aubrey et al., 2004) 
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HB2151) 
IgG Equine, murine  Hybridoma cells (in 
vivo hybridoma 
cultivation/ascite) 
  (Alvarenga et al., 2003) 
Human Hybridoma cells (in 
vitro hybridoma 
cultivation) 
1:4000  (Morine et al., 2008)  
Murine Hybridoma cells (in 
vivo hybridoma 
cultivation/ascite) 
  (Perez et al., 1984) 
  (Clot-Faybesse et al., 
1999)  
  (Frauches et al., 2013)  
  (Li et al., 1993)  
  (Alvarenga et al., 2005) 
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Hybridoma cells (in 
vitro hybridoma 
cultivation) 
  (Jia et al., 2000) 
Hybridoma cells   (Charpentier et al., 1990)  
IgG1 
 
Murine Hybdridoma cells (in 
vivo hybridoma 
cultivation/ascite) 
 Licea et al. describe a 
Fab fragment derived 
from the IgG originally 
produced by Zamudio et 
al. 
(Licea et al., 1996; F. 
Zamudio et al., 1992) 
  (Masathien et al., 1994, 
p. 3) 
Titres: 1:105 – 1:106  (Lomonte et al., 1992; 
Lomonte and Kahan, 
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1988)  
10.8 mg/mL  (Iddon et al., 1988) 
Hybridoma cells (in 
vitro hybridoma 
cultivation) 
  (Schneider et al., 2014) 
1/1024 for whole venom  (Fernandes et al., 2010) 
The greatest dilutions 
were of the order 104-105 
 (Tanjoni et al., 2003a, 
2003b) 
  (Bahraoui et al., 1988) 
IgG2 Murine Hybridoma cells (in 
vitro hybridoma 
cultivation) 
1/1024 for whole venom  (Fernandes et al., 2010) 
IgG2a Murine Hybridoma cells (in 
vivo hybridoma 
cultivation/ascite) 
  (Stiles et al., 1994) 
  (Trémeau et al., 1986) 
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IgG2b Murine Hybridoma cells (in 
vivo hybridoma 
cultivation/ascite) 
  (Stiles et al., 1994) 
  (Masathien et al., 1994, 
p. 3) 
IgM Murine Hybridoma cells (in 
vitro hybridoma 
cultivation) 
1/1024 for whole venom  (Fernandes et al., 2010) 
Hybdridoma cells (in 
vivo hybridoma 
cultivation/ascite) 
  (Masathien et al., 1994, 
p. 3) 
Ig Murine Hybridoma cells (in 
vivo hybridoma 
cultivation/ascite) 
2 mg/mouse  (Boulain et al., 1982) 
Hybridoma cells (in   (Dias-Lopes et al., 2014) 
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vitro hybridoma 
cultivation) 
 614 
 615 
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 616 
7. Targeting toxins of different toxicokinetic profiles and sites of action 617 
Animal venoms contain cocktails of toxins with a wide range of biological activities and variable 618 
toxicokinetic profiles. Some toxins, like elapid and scorpion neurotoxins, are low molecular mass proteins 619 
with a large volume of distribution, which allows them to rapidly reach systemic distribution and access 620 
extravascular targets in the peripheral nervous system. Other toxins, such as high molecular mass 621 
metalloproteinases and serine proteinases have a lower volume of distribution, and many of them act 622 
systemically within the vasculature, generating hemorrhage and coagulation disorders. Still, some toxins, 623 
particularly PLA2s and metalloproteinases, generate local tissue damage at the site of injection before 624 
reaching a systemic distribution. Other venomous animals that cause local tissue damage include brown 625 
spiders (Loxosceles spp.), whose venom can induce dermonecrotic lesions, although systemic manifestations 626 
are also observed, including acute kidney injury (Chaim et al., 2006). Thus, these different toxicokinetic 627 
scenarios and the consequent profile of toxicity associated with the various types of toxins demand a detailed 628 
consideration when designing the most effective antibody format for neutralization. Locally acting toxins are 629 
possibly better neutralized by Fabs, scFvs, or VHHs, as these fragments better reach and neutralize toxins in 630 
deep tissue compartments compared to IgGs (Fig. 7D), which largely remain within blood vessels. 631 
Unfortunately, biodistribution studies involving these fragments and their use as antivenoms are scarce. 632 
However, other studies involving anti-tumor antibodies have already demonstrated their rapid and efficient 633 
tissue penetration, in which scFvs exhibited fast and high penetration in the tumor mass, while Fabs 634 
demonstrated intermediate tissue penetration in comparison to IgGs (Yokota et al., 1992). In contrast, an in 635 
vivo study using mice envenomed with B. asper venom, demonstrated that IgG and F(ab’)2 were in fact 636 
capable of reaching muscle tissue, although the researchers pointed out that the observed antibody 637 
accumulation could be a result of venom-induced microvascular alterations, which could increase the 638 
antibodies extravasation (León et al., 2001). Interestingly, no differences in the ability to neutralize local tissue 639 
damage between IgG, F(ab’)2, and Fab antivenoms were observed, probably owing to the effects of tissue 640 
damage on antivenom PK (León et al., 2000, 1997). Thus, antivenom PK is affected by the pathological 641 
changes induced by venoms in the tissues, and this must be considered when discussing the best antibody 642 
format for a given type of envenoming. 643 
Systemically acting toxins are known to induce systemic toxic effects, including neuromuscular 644 
blockade, bleeding, coagulopathies, acute kidney injury and cardiovascular shock, among others (Gutiérrez et 645 
al., 2017a). Neurotoxins represent a relevant example, since they need to reach extravascular targets in the 646 
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peripheral nervous system to exert their actions. Venoms from scorpions, spiders and elapid snakes are rich 647 
sources of neurotoxins (Del Brutto, 2013; Escoubas et al., 2000; Kini and Doley, 2010; Laustsen et al., 2016a, 648 
2016c). The best antibody format to treat systemically acting toxins may be one that enables rapid diffusion to 649 
the tissues to bind and neutralize toxins that have reached systemic tissue targets (see section 3). On the other 650 
hand, the long half-life of the IgG provides prolonged protection from toxins remaining in the circulation, 651 
such as high molecular mass metalloproteinases and serine proteinases, or toxins escaping the bite site at late 652 
stages of envenoming, which is beneficial in cases where toxins leak from the bite wound over the course of 653 
days. In these circumstances, the prolonged half-life of IgG ensures that toxins remaining in the circulation or 654 
getting access to the circulation at later time periods would be bound and neutralized. Thus, the optimal 655 
antibody format has to be analyzed on a case by case basis, and it is likely that formulations that combine high 656 
and low molecular mass formats may be the optimal solution in many cases (Gutiérrez et al., 2003). 657 
Toxin neutralization has generally been considered to take place when a toxin is bound by the variable 658 
region of an antibody. Therefore, antivenoms used in passive immunotherapy are frequently prepared using 659 
Fab/F(ab’)2 formats to limit immunogenicity and the risk of serum sickness. However, with the possibility of 660 
using monoclonal human antibodies, the Fc region has gained renewed interest (Laustsen et al., 2017; Richard 661 
et al., 2013), as it dramatically increases antibody plasma half-life. The attached Fc domain also enables the 662 
interaction with Fc-receptors found on immune cells, a feature that is particularly important for clearance 663 
mechanisms. Additionally, from a biophysical perspective, the Fc domain folds independently and can 664 
improve the solubility and stability of the antibody molecule (Kontermann, 2011; Nimmerjahn and Ravetch, 665 
2008). Use of the human Fc domain of novel monoclonal toxin-targeting antibodies thus deserves further 666 
investigation – particularly for targeting systemically acting toxins. 667 
 668 
8. Conclusions and predictions 669 
With the renewed focus on snakebite as a neglected tropical disease by the WHO (Gutiérrez et al., 670 
2017a) a hope emerges that research efforts within developing novel envenoming therapies will be intensified. 671 
This may not only contribute to the development of a new generation of antivenoms for treating envenomed 672 
snakebite victims, but it may also pave the way for novel antivenoms against envenomings by other animals. 673 
In the field of antivenom, antibody technologies have been introduced several decades ago, although with 674 
very limited efforts compared to the fields of oncology, autoimmune diseases, and infectious diseases. Despite 675 
its nascent state, research within monoclonal antibodies against animal toxins is thus well-positioned to 676 
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harness the developments from these other fields that have made major progress in antibody discovery 677 
technologies, antibody engineering approaches, and antibody manufacturing. 678 
Based on what is known from the field of antivenom research itself and general knowledge on 679 
monoclonal antibodies, it seems likely that different antibody formats may be applicable for different types of 680 
envenomings. An urgent need exists for targeting locally acting toxins with better efficacy within snakebite 681 
envenomings (Gutiérrez et al., 2017a). However, improvements in monoclonal human IgG discovery and 682 
development also open a door for improved therapies targeting systemically acting toxins. Generally, a trend 683 
in antivenom research seems to present itself as a move away from the use of immunization, hybridoma 684 
technology, and murine antibodies towards phage display technology and human and camelid antibodies 685 
instead (Laustsen, n.d.; Roncolato et al., 2015). One possible prediction may be that combinatorial approaches 686 
merging (novel) immunization techniques and phage display may be introduced into the field of antivenom 687 
R&D, as transgenic animals engineered to contain the human antibody repertoire become more widely 688 
available to academia. This would allow researchers to obtain human antibody mRNA from immunized 689 
transgenic animals and use this mRNA to construct affinity matured fully human antibody phage display 690 
libraries. In turn, such libraries could be employed in a high-throughput fashion for discovery of a multitude 691 
of novel toxin-targeting human antibodies. As auxiliary tools for guiding antivenom developing, novel 692 
approaches within determination of antibody cross-reactivity may accelerate development of novel 693 
antivenoms. Particularly promising technologies include antivenomics, which may provide a holistic view of 694 
the toxin-capturing abilities of antibodies, and high-density peptide microarray, which can provide amino acid 695 
level resolution of epitope-paratope interactions between toxins and antibodies (Engmark et al., 2017b, 2016). 696 
Finally, it is possible that other display technologies (e.g. mammalian display (Bowers et al., 2014; Ho and 697 
Pastan, 2009)) and novel binding protein formats, such as DARPins (designed ankyrin repeat proteins) 698 
(Rasool et al., 2016; Stumpp et al., 2008), Armadillo repeat proteins (Varadamsetty et al., 2012), Affitins 699 
(Béhar et al., 2016; Correa et al., 2014; Pacheco et al., 2014), Adhirons (Tiede et al., 2014), Anticalins 700 
(Schiefner and Skerra, 2015), and various other protein scaffolds (Simeon and Chen, 2017) may find their way 701 
into the field of antivenom development. 702 
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Figures 1648 
Figure 1. Disadvantages of current animal plasma-derived antivenoms. Early adverse reactions occur within 24 h 1649 
after administration of antivenoms. (A1) Patients may develop early adverse reactions (within 24 h) resulting from de 1650 
novo complement activation (non-IgE reactions) or, (A2) in cases of previous exposure to animal antibodies, due to 1651 
IgE-mediated anaphylactic reactions. (B) Around 70% or more of the antivenom antibodies are not directed towards 1652 
medically relevant venom toxins. Therefore, envenomed victims will receive a larger than necessary dose of equine 1653 
antibodies, which have no therapeutic value, but which may cause adverse reactions. (C) The large amount of antivenom 1654 
antibodies combined with elicited human anti-horse antibodies (IgGs and IgMs) may result in overproduction of immune 1655 
complexes. These may be deposited in blood vessels, glomeruli, and joints, mediating inflammation and promoting serum 1656 
sickness 1-2 weeks after administration of antivenom therapy. Black antibodies: equine antibodies specific to target 1657 
toxins. Red antibodies: equine antibodies against non-venom antigens. Blue antibodies: human antibodies against 1658 
equine antibodies. Green circles: Snake toxins. For the sake of simplicity, examples illustrating the disadvantages of 1659 
heterologous antibody therapy refer to equine antivenoms, but the same principles apply to antivenoms derived from other 1660 
animal species. 1661 
 1662 
Figure 2. Schematic overview of the different antibody formats used in existing plasma-derived antivenoms and 1663 
experimental recombinant antivenoms. IgG: whole IgG antibody. F(ab’)2: pepsin-digested IgG antigen-specific region. 1664 
Fab: papain-digested antigen-specific region. Diabody: non-covalent dimers of scFv fragments. scFv: single-chain 1665 
variable fragments. VHH: single-domain antigen-specific fragments. 1666 
 1667 
Figure 3. Modes of neutralization: Direct inhibition of non-enzymatic toxins. (A1) A non-enzymatic toxin binds to its 1668 
target, resulting in a toxic effect. (A2) The antibody interferes with the functional site of the non-enzymatic toxin, thereby 1669 
preventing the toxin binding to the target. Direct inhibition of enzymatic toxins. (B1) An enzymatic toxin binds to the 1670 
substrate resulting in enzymatic degradation of the substrate. (B2) The antibody blocks (or distorts) the catalytic site of the 1671 
enzymatic toxin, thereby preventing substrate degradation. Inhibition by steric hindrance. (C1) A toxin binds to its 1672 
target (toxin binding region in blue), resulting in a toxic effect. (C2) The antibody binds to a region near the site of 1673 
interaction, thereby preventing the toxin from binding to the target.      1674 
 1675 
Figure 4. Modes of neutralization: Allosteric inhibition. (1) A toxin binds to its target, resulting in a toxic effect. (2) 1676 
The antibody binds to a distal site of the toxin, which induces conformation changes, resulting in a less or non-functional 1677 
toxin (allosteric inhibition).  1678 
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 1679 
Figure 5. Modes of neutralization: Preventing dissociation. (1) A toxin complex is dissociated and the active toxins 1680 
bind to their targets, resulting in a toxic effect. (2) Antibody binding inhibits the dissociation of the toxin complex, thereby 1681 
preventing the formation of active toxins.  1682 
 1683 
Figure 6. Modes of neutralization: Preventing synergistic effects. (1) Synergism between toxin A (diamond) and B 1684 
(circle) results in synergistically enhanced toxicity. (2) Antibody binding to one of the toxins results in milder toxic (or 1685 
no) effects due to disruption of synergism. 1686 
 1687 
Figure 7. Antivenom pharmacokinetics. (A) Distribution profiles for different antibody formats, showing their volume 1688 
of distribution (Vd). (B) Elimination mechanism for different antibody formats, indicating their elimination half-life (t1/2). 1689 
(C) IgG recycling by FcRn receptor. 1. IgGs and plasma proteins are internalized in vesicles by endocytosis. 2. IgGs bind 1690 
to FcRn receptors in the acidic endososome. 3. Non-FcRn bound proteins. 4. Proteins are degraded in the lysosome. 5. 1691 
IgG-FcRn complexes are transported to the cell surface. 6. IgGs are dissociated from the FcRn receptors at physiological 1692 
pH. (D) The influence of the antibody format on pharmacokinetics in relation to toxicokinetics. The distribution of the 1693 
larger IgG antibody format is largely restricted to the intravascular compartment, where it is effective in neutralizing 1694 
systemically acting toxins over a period of many days due to its long elimination half-life. Smaller antibody fragments 1695 
may both neutralize toxins in circulation, toxins present in or around the bite wound, and toxins that have reached 1696 
systemic targets in tissues, i.e. neuromuscular junctions, due to their larger volumes of distribution, which allow these 1697 
smaller fragments to more effectively penetrate tissue compartments. However, antibody fragments have a shorter 1698 
elimination half-life. Systemically acting toxins are represented by scorpion stings and elapid snakebites, whereas viper 1699 
snakebites represent locally and systemically acting toxins, although all three types of bite/sting contain both locally and 1700 
systemically acting toxins in their venom. 1701 
 1702 
Figure 8. Schematic representation of three different CHO cells expressing three different glycosylated IgGs. The 1703 
mammalian cell line contains the necessary cellular components to produce properly folded and glycosylated IgGs. It has 1704 
been proposed that co-culturing such cell lines could be used for the production of recombinant antivenom based on 1705 
oligoclonal mixtures of (human) IgGs (Laustsen et al., 2017). 1706 
 1707 
 1708 
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Highlights 
• Comprehensive overview of reported antibodies against animal toxins 
• Pros and cons of antibody formats is discussed 
• Pharmacokinetics and pharmacodynamics of antibodies and their fragments 
• Trends in recombinant antivenom development are presented 
